

# Spartalizumab Biosimilar - Research Grade

**Product Code:** ICH5881

**More Information**

**Species Reactivity:** Human

**Target:** PDCD1 $\alpha$

**Concentration:** 5mg/ml

**Isotype:** IgG4 - kappa

**Host:** CHO Cells

**product name H2:** Spartalizumab Biosimilar - Research Grade

**Sequence:** <https://www.imgt.org/mAb-DB/>

**Buffer:** ICH3002

**UniProt:** Q15116

**Shipping Conditions:** Blue ice

**background:** PD-1 limits T-cell activation as an inhibitory checkpoint and is one of the most investigated targets in immuno-oncology. This reagent is an unconjugated, non-therapeutic analog of spartalizumab, a recombinant anti-PD-1 monoclonal antibody intended for research use only. It is manufactured to in vivo standards in a low-endotoxin format and offered in scalable milligram to gram quantities for high-throughput workflows. Researchers use it in checkpoint-blockade functional assays, in vitro T-cell co-culture screens, and in vivo tumor-immunology models requiring a consistent reagent. Its reproducible formulation and scalable volumes support standardized results in bulk research.

**Purification Method:** This monoclonal antibody was purified using Protein A



**Formulation:** Sterile, preservative-free, solution in PBS. BSA and Azide free.

**Purity:** >90% by SDS-PAGE

**Endotoxin:**  $\leq 1.0$  EU/mg as determined by the LAL method

**Storage:** This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

**Applications:** Functional Assays

**Application Notes:** This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

**Use:** Products are for research use only. Not for use in diagnostic or therapeutic procedures.

**Delivery Time:** 3-4 weeks